cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Elmiawati Latifah
Contact Email
elmiawatilatifah@ummgl.ac.id
Phone
+6281392212213
Journal Mail Official
journal.psp@ummgl.ac.id
Editorial Address
Universitas Muhammadiyah Magelang, Jl. Mayjen Bambang Soegeng, Glagak, Sumberrejo, Kec. Mertoyudan, Magelang, Jawa Tengah 56172, Indonesia
Location
Kab. magelang,
Jawa tengah
INDONESIA
Jurnal Farmasi Sains dan Praktis
Published by Universitas Muhammadiyah Magelang
ISSN : 25499068     EISSN : 25794558     DOI : -
Core Subject : Health, Science,
Immunology & microbiology Medicine & Pharmacology Public Health
Jurnal Farmasi Sains dan Praktis aims to serve the updated scientific knowledge for international researchers in pharmaceutical sciences. Jurnal Farmasi Sains dan Praktis (JFSP) publishes review article, original article, as well as short communication in the all scopes of Pharmaceutical Science such as Pharmaceutics, Biopharmaceutics, Drug Delivery System, Physical Pharmacy, Pharmaceutical Technology, Pharmaceutical Microbiology and Biotechnology, Pharmacology and Toxicology, Pharmacokinetics, Pharmaceutical Chemistry, Pharmaceutical Biology, Community and Clinical Pharmacy, Pharmaceutical Marketing, Alternative Medicines, Pharmaceutical Management, Pharmacoeconomic, Pharmacoepidemiology, Social Pharmacy, Pharmacy Policies.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Ilmu Farmasi
Articles 9 Documents
 1 
Search results for , issue "Vol 11 No 2 (May-August 2025)" : 9 Documents clear
POTENTIAL OF ROSELLA FLOWER EXTRACT KEFIR (HIBISCUS SABDARIFFA L.) IN REDUCING PANCREATIC β- CELL DAMAGE IN DIABETES MELLITUS MODEL RATS (RATTUS NORVEGICUS) Anggi, Viani; Tandi, Joni; D, Rahmawati; M, Yulan; L, Wahyudin H
Jurnal Farmasi Sains dan Praktis Vol 11 No 2 (May-August 2025)
Publisher : Universitas Muhammadiyah Magelang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31603/pharmacy.v11i2.8197

Abstract

Kefir is a fermented milk product that contains probiotics, while rosella flowers (Hibiscus sabdariffa L.) are known to have antioxidant and antihyperglycemic activity. The combination of the two in the form of rosella flower extract kefir is expected to have a protective effect on the pancreas in diabetes. This study aims to evaluate the effect of administering rosella flower extract kefir preparations on the histopathological appearance of the pancreas of male white rats (Rattus norvegicus) induced by streptozotocin.This experimental study used a post-test control group design using 30 male white rats divided into several groups, namely normal controls who were given Na CMC 0.5% orally for 21 days, negative controls (induced by STZ without treatment) given Na CMC 0.5% orally for 21 days, positive controls (induced by STZ) and given glibenclamide suspension 0.45 mg/kg WB orally for 21 days, and treatment groups with different doses from kefir rosella flower extract with graded doses of 250 mg/kg BW, 500 mg/kg BW and 750 mg/kg BW. After treatment, rat pancreas was collected and analyzed histopathologically. The results of histopathological analysis showed that the group of mice that received rosella flower extract kefir at a dose of 750 mg/kg BW experienced structural improvements in pancreatic β cells with a damage value of 0.4. Administration of rosella flower extract kefir at a dose of 750 mg/kg BW has the potential to provide a protective effect on the pancreas in rats induced by streptozotocin
EXPLORING THE ROLE OF DRUGBANK IN INVESTIGATING PHARMACOGENOMIC-DRIVEN NOVEL DRUG Santoso, Setiyo Budi; Pribadi, Prasojo; Hapsari, Widarika Santi; Abiyana, Setya Rini
Jurnal Farmasi Sains dan Praktis Vol 11 No 2 (May-August 2025)
Publisher : Universitas Muhammadiyah Magelang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31603/pharmacy.v11i2.10283

Abstract

Bioinformatics plays a vital role in drug discovery and repurposing, yet challenges persist in data availability, biological complexity, and method standardization. The continued exploration and utilization of resources such as DrugBank will play a crucial role in advancing drug development and uncovering novel therapeutic opportunities. Our study presents a comprehensive analysis of the methodology utilized by bioinformaticians to integrate DrugBank with multiple databases, with the aim of facilitating the discovery of novel drugs. A literature review was conducted using Scopus and PubMed, focusing on articles from the last 10 years. Relevant articles meeting the inclusion criteria were collected between October and November 2022. The review identified 35 unique papers after removing duplicates. Screening led to 9 papers meeting inclusion criteria. The study reveals that DrugBank is an indispensable resource, aiding drug-gene interaction analysis and connecting gene data sources with potential drug candidates. It streamlines the multinetworking process and enables the identification and validation of new medications through clinical tools. These findings shed light on drug-gene interactions and drug repurposing, emphasizing the significance of leveraging multiple databases and network data. DrugBank's pivotal role in advancing drug discovery and personalized medicine underscores its importance in bioinformatics research.
ANALYSIS AND VALIDATION OF DETECTION METHOD FOR ETHYLENE AND DIETHYLENE GLYCOL CONTAMINANTS IN SYRUP USING GCMS (GAS CHROMATOGRAPHY-MASS SPECTROMETER) Supandi, Supandi; Mustafidah, Mabrurotul; Yaenap, Siti; Rumblat, Walid
Jurnal Farmasi Sains dan Praktis Vol 11 No 2 (May-August 2025)
Publisher : Universitas Muhammadiyah Magelang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31603/pharmacy.v11i2.11180

Abstract

Ethylene glycol (EG) and diethylene glycol (DEG) are hazardous compounds if ingested by the human body. Testing conducted by the Indonesian National Agency of Drug and Food Control (BPM) identified contamination of EG and DEG in glycerin and propylene glycol, which are utilized as solubility enhancers in syrup-based pharmaceuticals. This study aims to analyze EG and DEG contamination in children’s syrup drug samples using a Gas Chromatography-Mass Spectrometry (GC-MS) instrument. This study presents an analytical method for detecting EG and DEG contamination. Based on BPOM regulations governing the control a determination of EG and DEG. Several syrup drug samples, which are listed in the BPOM drug withdrawal list under Number HM.01.1.2.11.22.240, were each weighed at 5 grams, transferred into a 50 mL volumetric flask, 30 mL of methanol was added, and the mixture was sonicated for 5 minutes. Subsequently, solvent was added up to the calibration mark. Five out of eight samples were found to contain EG and DEG at concentrations of less than 0.1%. Validation of the GCMS method for EG and DEG compounds yielded accuracy values with recovery rates between 98% and 101%. The acquisition test results produced a relative standard deviation (RSD) value of 0.87. The linearity test showed a correlation coefficient (r) of 0.955. The limit of detection (LOD) for EG was 0.26 ng/mg, and for DEG it was 0.51 ng/mg. The limit of quantification (LOQ) for EG was 0.86 ng/mg, and for DEG it was 1.69 ng/mg. This validation indicates that the analytical method exhibits high accuracy and sensitivity.
STUDY OF ADVERSE DRUG REACTIONS OF LINEZOLID IN DRUG RESISTANT TUBERCULOSIS PATIENTS Susilo, Rinto; Sundhani, Elza; Setyaningsih, Indah; Retnaningsih, Ririn; Nurjanah, Ucu; Endang Ayu Prihatini, Nok
Jurnal Farmasi Sains dan Praktis Vol 11 No 2 (May-August 2025)
Publisher : Universitas Muhammadiyah Magelang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31603/pharmacy.v11i2.12472

Abstract

The estimated number of DR TB patients in Indonesia is increasing. High adverse drug reactions have the potential to affect the success of DR TB patient treatment. Linezolid is one of the drugs in combination with DR TB therapy that has the potential to cause adverse drug reactions in the form of hematological disorders and visual impairment. This study aims to determine the incidence of Linezolid ADRs, including the incidence, severity, and risk factors associated with the occurrence of ADRs. This type of study is observational with a cross-sectional design conducted retrospectively in DR TB patients at the lung clinic of Hospital 'X" and Hospital "Y" in Indonesia. The results of the study showed that the incidence of ADRs suspected of Linezolid that met the criteria was 70 patients out of a total of 215. The most common type of ADRs was hematological disorders at 89%, the rest were visual impairment. The type of regimen and type of ADRs correlate with the severity of ADRs. It is necessary to monitor drug levels in the blood in order to monitor and prevent the potential for more severe ADRs so that therapy can be individualized.
ANALYSIS OF ADVERSE DRUG REACTIONS (ADRs) AND THEIR SEVERITY IN BREAST CANCER PATIENTS TREATED WITH THE DOCETAXEL-DOXORUBICIN REGIMEN AT SULTAN AGUNG ISLAMIC HOSPITAL Setiaji, Muh Maskur; Cholisoh, Zakky
Jurnal Farmasi Sains dan Praktis Vol 11 No 2 (May-August 2025)
Publisher : Universitas Muhammadiyah Magelang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31603/pharmacy.v11i2.12956

Abstract

The use of the docetaxel-doxorubicin regimen in breast cancer treatment has been associated with Adverse Drug Reactions (ADRs). This study aims to analyze the occurrence of ADRs and their severity in breast cancer patients undergoing therapy with the docetaxel-doxorubicin regimen at the hospital. The research design employed a quantitative cross-sectional approach, and purposive sampling was used as the sampling technique. Six primary Adverse Drug Reactions (ADRs) were identified among breast cancer patients undergoing chemotherapy with the docetaxel-doxorubicin regimen: nausea (21,32%), anemia (13,71%), peripheral neuropathy (7,45%), alopecia (23,01%), cardiac disorders (7,11%), and anorexia (9.81%). Breast cancer patients treated with the docetaxel doxorubicin regimen experienced various levels of ADR severity. Among the 591 adverse drug reaction (ADR) incidents recorded, the majority (55.6%) were classified as mild (severity level 1), with nausea reported as the most common side effect. At severity level 2 (moderate), alopecia was predominant, while at severity level 3 (severe), anemia was the most common reaction. There were no ADR incidents reported at severity levels 4 and 5
PRINCIPLES OF DOSE ADJUSTMENT IN PATIENTS WITH CHRONIC KIDNEY FAILURE Mende, Juniarto; Kartikawati, Nurfina Dian; Titami, Arina; Mahmuda, Hartati
Jurnal Farmasi Sains dan Praktis Vol 11 No 2 (May-August 2025)
Publisher : Universitas Muhammadiyah Magelang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31603/pharmacy.v11i2.9687

Abstract

Chronic renal disease is a kidney illness marked by a progressive decline in kidney function over months or years. The usage of medications in this condition is a crucial aspect of managing kidney disease patients. When done correctly, pharmacotherapy can halt disease development and minimize morbidity and mortality. In patients with kidney illness, decreasing kidney function can drastically change the pharmacokinetics and pharmacodynamics of many medications, increase the risk of drug toxicity if not well treat. Many of these changes must be expected and mitigated by changing the medicine dosage. Complications of chronic kidney disease (CKD) that go untreated can cause significant early morbidity and mortality, as well as aggravate its progression. This literature review is based on a review of the literature and articles related to CKD to determine the principles of dose adjustment in CKD patients. Classification of drugs in CKD patients includes antifungals, anticoagulants, antidiabetics, antihypertensives, antibiotics, and analgesics. The administration of these drugs should be considered for kidney function in CKD patients. The presence of multidisciplinary interventions reduces the risk of progression of CKD severity. Adjustment of the dosage regimen in CKD patients is carried out for certain drugs that have a significant relationship between drug concentration and clinical outcomes in patients.
THE INFLUENCE OF COST-FACIT AND HEALTH-RELATED QUALITY OF LIFE IN CANCER PATIENTS: A NARRATIVE REVIEW Wulandari, Aprilla Ayu; Andayani, Tri Murti; Endarti, Dwi; Pratiwi, Woro Rukmi
Jurnal Farmasi Sains dan Praktis Vol 11 No 2 (May-August 2025)
Publisher : Universitas Muhammadiyah Magelang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31603/pharmacy.v11i2.7220

Abstract

COST-FACIT is a financial toxicity measurement instrument that has been validated in several countries. Financial toxicity is a broad term that includes the costs a patient has to bear after a cancer diagnosis, which impacts personal and family budgets. This has implications for increasing awareness of the financial toxicity experienced by cancer patients so that it can support better policies and funding decisions by hospital management and the government. This article is a Narrative Review on studies regarding the influence of COST-FACIT and HRQoL in cancer patients. Search for English articles using the Pubmed, ScienceDirect, and Google Scholar databases, which were published from 2012 to 2022. Based on the Narrative Review that has been done, there are 19 articles that meet the criteria. In the article there are various HRQoL dimensions that are correlated with COST-FACIT. Dimensions that have a moderate to strong influence are psychological (emotional) and financial because the occurrence of financial toxicity can disrupt family expenses every month. If this continues, it can result in psychological distress for the patients and their family.
QUALITY TEST OF SAPPAN WOOD (Caesalpinia sappan L.) EXTRACT TONER Prasdiantika, Ricka; Saraswati, Nanda; Tolkhah, Ronal
Jurnal Farmasi Sains dan Praktis Vol 11 No 2 (May-August 2025)
Publisher : Universitas Muhammadiyah Magelang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31603/pharmacy.v11i2.11813

Abstract

The skin is the body's outermost organ that continuously interacts with the surrounding environment. Free radical exposure, unpredictable weather, and outdoor activities cause skin damage, necessitating the use of skincare products such as toners containing antioxidants. Natural antioxidants could be obtained from woody plants like sappanwood (Caesalpinia sappan L.). This research aimed to create a toner preparation from sappanwood extract and test the physical quality of the preparation. The quality tests conducted on the toner preparation included organoleptic, pH, homogeneity, and viscosity tests. The method used in this research was quantitative descriptive. The toner preparation was made in four variations of sappanwood extract concentrations: 0%, 1%, 2%, and 4%. The organoleptic test results showed that all four formulas had a liquid form and an oleum rosae scent. F0 was clear in color, FI was red, FII was dark red, and FIII was reddish-brown. The pH test results for F0, FI, FII, and FIII were 5.43±0.015, 5.16±0.006, 5.02±0.006, and 4.96±0.006, respectively. The homogeneity test results for all four formulas showed homogeneous results, with no coarse particles or clumps. The viscosity test results F0, FI, FII, and FIII were 3.17±0.058 cP, 3.67±0.058 cP, 3.83±0.058 cP, and 3.97±0.058 cP, respectively. The results of the organoleptic, pH, homogeneity, and viscosity tests indicated that the sappanwood extract toner preparation met the requirements for a skin-cleansing toner.
COST-EFFECTIVENESS ANALYSIS OF AMLODIPINE AND CANDESARTAN USE IN TYPE 2 DIABETES MELLITUS PATIENTS WITH COMORBID HYPERTENSION IN YOGYAKARTA, INDONESIA Hadning, Ingenida; Riswana, Nabila Uswah; Ardhani, Nariswari Cahya; Arini, Merita
Jurnal Farmasi Sains dan Praktis Vol 11 No 2 (May-August 2025)
Publisher : Universitas Muhammadiyah Magelang

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Type 2 diabetes mellitus, often accompanied by comorbid hypertension, necessitates expensive and prolonged treatment. Therefore, conducting a cost-effectiveness analysis is crucial to identify the most economically viable option by comparing the costs and therapeutic efficacy of amlodipine and candesartan in patients with type 2 diabetes mellitus and comorbid hypertension in Yogyakarta, Indonesia. This research aims to analyze therapy costs and effectiveness using pharmacoeconomic assessment, specifically calculating ACER (Average Cost-Effectiveness Ratio) and ICER (Incremental Cost-Effectiveness Ratio) values. The study uses a quantitative approach with retrospective data collection from patient medical records through total sampling. This research gathered data from 149 medical records. The cost-effectiveness analysis based on ACER values revealed the following: amlodipine 5 mg cost IDR 86; amlodipine 10 mg cost IDR 51; candesartan 8 mg cost IDR 571; candesartan 16 mg cost IDR 727. The ICER value of amlodipine 5 mg – candesartan 8 mg cost IDR 1,527; amlodipine 5 mg – candesartan 16 mg cost IDR 2,192; amlodipine 10 mg – candesartan 8 mg cost IDR –8454; amlodipin 10 mg – candesartan 16 mg cost IDR –5,979. The therapy is considered cost-effective when the ACER value is low, and the negative value of ICER indicates that the treatment has lower costs with greater effectiveness. So, using amlodipine 10 mg is the most cost-effective approach for reducing blood pressure in type 2 diabetes mellitus patients with comorbid hypertension in Yogyakarta, Indonesia.

Page 1 of 1 | Total Record : 9

 1 

Filter by Year

2025 2025


Reset
Filter By Issues
All Issue Vol 11 No 3 (September-December 2025) Vol 11 No 2 (May-August 2025) Vol 11 No 1 (January-April 2025) Vol 10 No 3 (September-December 2024) Vol 10 No 2 (May-August 2024) Vol 10 No 1 (January-April 2024) Vol 9 No 3 (September-December 2023) Vol 9 No 2 (May-August 2023) Vol 9 No 1 (January-April 2023) Vol 8 No 3 (September-December 2022) Vol 8 No 2 (May-August 2022) Vol 8 No 1 (January-April 2022) Vol 7 No 3 (2021): Supplementary Issue (The 4th National Pharmacy Conference 2021 Universitas Halu O Vol 7 No 2 (2021) Vol 7 No 1 (2021) Vol 6 No 2 (2020) Vol 6 No 1 (2020) Vol 5 No 2 (2019) Vol 5 No 1 (2019) Vol 4 No 2 (2018) Vol 4 No 1 (2018) Vol 3 No 2 (2017) Vol 3 No 1 (2017) Vol 2 No 1 (2016) Vol 1 No 2 (2016) Vol 1 No 1 (2015) More Issue